Nasdaq: ABUS
Arbutus Biopharma insiders
The officers, directors and 10% owners of Arbutus Biopharma Corporation who hold the most stock, valued at the live ABUS price.
$4.07
ABUS today −$40K (−0.97%)
Market closed. Prices as of Nov 19, 4:04 PM ET
- Ranked insiders
- 4
- Their ABUS stock
- $135M
- Market value
- $624M
- Held by ranked insiders
- 21.7%
Insiders by value of ABUS holdings
SEC ownership page| # | Insider | Role | Shares | Value | Of company | Overall rank |
|---|---|---|---|---|---|---|
| 1 | Matthew Gline | Director | 29,880,079 | $122M | 19.5% | 333rd |
| 2 | Michael J. McElhaugh | Interim President & CEO | 1,658,003 | $6.7M | 1.08% | 11701st |
| 3 | Michael J. Sofia | Chief Scientific Officer | 1,652,283 | $6.7M | 1.08% | 11733rd |
| 4 | Keith Manchester | Director | 46,069 | $188K | <0.1% | 519th |
Only insiders worth at least $5 million in listed stock are ranked. Holdings come from each insider's latest Form 3, 4 or 5 for Arbutus Biopharma; see each profile for the filing.